Dr Reddys launches Vigabatrin Tablets in US market

Dr Reddys Laboratories announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril (vigabatrin) Tablets, USP, approved by the U.S. Food and Drug Administration (USFDA).

The Sabril brand and generic had U.S. sales of approximately $141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health.

Dr. Reddy's Vigabatrin Tablets, USP are available in 500 mg tablets in a bottle count size of 100.

Powered by Capital Market - Live News